KEWAUNEE SCIENTIFIC CORP /DE/ (KEQU) Form 8-K — Sep 9, 2026
Kewaunee Scientific Corporation (NASDAQ: KEQU) reported first-quarter fiscal 2027 results for the quarter ended July 31, 2026, with sales of $66.3 million, down 6.7% from $71.1 million a year earlier. Pre-tax earnings fell 34.7% to $2.6 million, net earnings were $1.7 million versus $3.1 million, and diluted EPS came in at $0.58 versus $1.04 in the prior-year quarter. Order backlog rose sequentially to $169.0 million from $165.9 million at April 30, 2026, but remains well below the $205.0 million recorded on July 31, 2025.
Key figures
- Eps
- $0.58 diluted (vs. $1.04 prior-year quarter)
- Revenue
- 66320000
- Net Income
- 1706000
- Total Debt
- short-term $6,478,000; long-term $39,377,000 (long-term debt excluding sale-leaseback obligation: $13,844,000)
- Revenue Yoy
- -6.7%
- Total Assets
- 175800000
- Cash Position
- 10261000
- Ebitda
- 4525000
- Backlog
- $169.0 million at July 31, 2026 (vs. $165.9 million at April 30, 2026 and $205.0 million at July 31, 2025)
- Debt To Equity
- 0.59-to-1 (0.25-to-1 excluding sale-leaseback)
- Pretax Earnings
- 2560000
- Working Capital
- 56716000
- Lpg Segment Sales
- 50868000
- Prior Year Ebitda
- 6320000
- Prior Year Revenue
- 71104000
- Pretax Earnings Yoy
- -34.7%
- Prior Year Net Earnings
- 3093000
- International Segment Sales
- 15452000
- International Net Earnings Growth
- +23.5%
- One Time Compensation Expense Context
- cash settlement of long-term incentive awards in lieu of shares; not expected to recur
Price after filing
Close on the filing date to close N calendar days later (from $36.99). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.